PITTSBURGH, March 21 /PRNewswire/ -- Dr. Doros Platika, M.D., President and Chief Executive Officer of The Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region's life sciences industry on a fast track for growth, today announced that PLSG has invested $100,000 in Applied Isotope Technologies, Inc., (AIT), a Pittsburgh-based firm that is developing a family of proprietary high-value reagents and standards for minute amounts of samples analyzed by academic, non-profit and commercial laboratories. The investment is provided under the PLSG's Technology Development Fund (TDF) program.
About Applied Isotope TechnologiesSince its incorporation in 2003, AIT has entirely focused on creation of new technologies, quantitative measurement tools, and related products and services for analyses in environmental, biological markets, and in early cancer detection. The company's products play a critical role in providing significantly improved levels of accuracy, sensitivity and convenience in trace and sub-trace analyses using an important class of analytical instruments called mass spectrometers. Trace compounds are typically measured in nanogram or even lower quantities.
Over the past ten years, Mass Spectrometry ("MS") has become the dominant analytical instrument for detection of analytes that must be measured at very small quantities.
The ability to identify and accurately measure complex chemical structures by the MS, in speciated forms, possible only through the application of the species-specific isotope dilution analysis (SIDMS) promises to be significant and transformational in several multi-billion dollar industries.
"We are very pleased with our new relationship with PLSG. The TDF investment is earmarked for the development of important new measurement protocols and related standards, reagents and software for human health care. These products will be developed in collaboration with scientists from the Centers for Disease Control (CDC) and National Institute of Standards and Technology (NIST), and used to accurately detect many harmful and sometimes chemo-preventive elemental chemical species, such as selenium in human blood, urine, tissue and hair that are presently impossible to do," said Matt Pamuku, President and CEO of Applied Isotope Technologies, Inc.
About the Technology Development Fund (TDF) The Technology Development Fund is a competitive funding program designed to increase the commercialization potential of life science technologies developed by the region's scientists and entrepreneurs. The intent is to provide financial support to verify the technical and commercial feasibility of early stage inventions that will accelerate and increase the likelihood that the technology will be successfully commercialized through a regional start-up company. These funds can be used in conjunction with or to leverage other early sources of funding.
About the PLSG The Pittsburgh Life Sciences Greenhouse is a public/private partnership, founded by the University of Pittsburgh, Carnegie Mellon University, UPMC Health System, the Commonwealth of Pennsylvania and its regional foundation community. Together with private industry and advanced research and healthcare capabilities of our institutional partners, PLSG invests in and supports the growth of regional life sciences companies in the areas of: bioinformatics; bionanotechnology; diagnostics; medical devices; medical robotics; therapeutics; and tools and services.
SOURCE: Pittsburgh Life Sciences Greenhouse
Related Information
EVISA Database on Companies: Applied Isotope Technologies Pittsburgh Life Sciences Greenhouse Web Site: http://www.plsg.com
last time modified: June 20, 2020
